Inventiva S.A (IVEVF PINK) stock market data APIs
$2.2709
0(0%)
as of July 14, 2025
Try our APIs with
free plan!
Inventiva S.A Financial Data Overview
Price chart is built with
Anychart
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
Prev. Close
2.2709
Open
2.2709
High
2.2709
Low
2.2709
52 wk Range
2.28-3.64
Market Cap
499 M
Shares Outstanding
139 M
Revenue
14 094 K
EPS
-0.4384
Beta
0.618
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inventiva S.A data using free add-ons & libraries
Get Inventiva S.A Fundamental Data
Inventiva S.A Fundamental data includes:
- Net Revenue: 14 094 K
- EBITDA: -93 762 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-05-12
- EPS/Forecast: -0.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inventiva S.A News
New
Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target
Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ:IVA)...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
INVENTIVA Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company fo...
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
INVENTIVA Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH. This second tranche carries an inter...
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
INVENTIVA The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
